| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, General Counsel
1 company
Basta James is an EVP, General Counsel at NTLA. Recent filings cover 0 purchases and 7 sales. Those positions are worth an estimated $1.2M at current prices.
Our model assigns Basta James a strong insider score of 72/100, based on 7 past trades. Over a 12-month horizon, 83.3% of those trades were profitable, with an average 12-month return of +25.5%.
Basta James's largest disclosed position is in NTLA as EVP, General Counsel, worth about $1.2M. The recent filings there lean toward selling, a net 28,371 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 10,397 | $9.21 | $95,756.37 | -9.3% | +41.9% | - | |
| Mar 4, 2025 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 2,572 | $8.99 | $23,122.28 | -2.2% | -21.3% | +52.0% | |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 7,074 | $12.18 | $86,161.32 | -8.7% | -43.2% | -24.1% | |
| Mar 4, 2024 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 2,297 | $32.99 | $75,778.03 | -2.7% | -27.4% | -71.9% | |
| Jan 3, 2024 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 3,805 | $29.46 | $112,095.30 | -6.9% | -14.9% | -58.6% | |
| Mar 2, 2023 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 1,088 | $43.88 | $47,741.44 | -1.9% | -15.3% | -25.8% | |
| Jan 4, 2023 | NTLA Intellia Therapeutics, Inc. | EVP, General Counsel | Sell | 1,138 | $37.21 | $42,344.98 | -5.5% | -7.5% | -24.6% |